Evaluation of Adherence and Persistence Differences Between Adalimumab Citrate-Free and Citrate Formulations for Patients with Immune-Mediated Diseases in the United States
Crossref DOI link: https://doi.org/10.1007/s40744-020-00256-x
Published Online: 2020-11-21
Published Print: 2021-03
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Bergman, Martin
Patel, Pankaj
Chen, Naijun
Jing, Yonghua
Saffore, Christopher D.
Funding for this research was provided by:
AbbVie
Text and Data Mining valid from 2020-11-21
Version of Record valid from 2020-11-21
Article History
Received: 19 October 2020
Accepted: 7 November 2020
First Online: 21 November 2020